AISep 17, 2023

Using Reinforcement Learning to Simplify Mealtime Insulin Dosing for People with Type 1 Diabetes: In-Silico Experiments

arXiv:2309.09125v16 citationsh-index: 6
Originality Incremental advance
AI Analysis

This work addresses the challenge of insulin dosing for individuals with type 1 diabetes, offering a potential simplification of treatment, though it is incremental as it builds on existing reinforcement learning methods applied to a specific domain.

The paper tackled the problem of simplifying mealtime insulin dosing for people with type 1 diabetes by proposing a reinforcement learning agent that recommends doses without precise carbohydrate counting, achieving a time-in-range of 73.1% and time-in-hypoglycemia of 2.0% in in-silico experiments.

People with type 1 diabetes (T1D) struggle to calculate the optimal insulin dose at mealtime, especially when under multiple daily injections (MDI) therapy. Effectively, they will not always perform rigorous and precise calculations, but occasionally, they might rely on intuition and previous experience. Reinforcement learning (RL) has shown outstanding results in outperforming humans on tasks requiring intuition and learning from experience. In this work, we propose an RL agent that recommends the optimal meal-accompanying insulin dose corresponding to a qualitative meal (QM) strategy that does not require precise carbohydrate counting (CC) (e.g., a usual meal at noon.). The agent is trained using the soft actor-critic approach and comprises long short-term memory (LSTM) neurons. For training, eighty virtual subjects (VS) of the FDA-accepted UVA/Padova T1D adult population were simulated using MDI therapy and QM strategy. For validation, the remaining twenty VS were examined in 26-week scenarios, including intra- and inter-day variabilities in glucose. \textit{In-silico} results showed that the proposed RL approach outperforms a baseline run-to-run approach and can replace the standard CC approach. Specifically, after 26 weeks, the time-in-range ($70-180$mg/dL) and time-in-hypoglycemia ($<70$mg/dL) were $73.1\pm11.6$% and $ 2.0\pm 1.8$% using the RL-optimized QM strategy compared to $70.6\pm14.8$% and $ 1.5\pm 1.5$% using CC. Such an approach can simplify diabetes treatment, resulting in improved quality of life and glycemic outcomes.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes